State of the Art: Interventional Pulmonology

Momen M. Wahidi; Felix J.F. Herth; Alexander Chen; George Cheng; Lonny Yarmus

doi:10.1016/j.chest.2019.10.013

State of the Art: Interventional Pulmonology

Momen M. Wahidi^*, Felix J.F. Herth, Alexander Chen, George Cheng, Lonny Yarmus

^*Corresponding author for this work

Medicine, Pulmonary Division

Research output: Contribution to journal › Review article › peer-review

35 Scopus citations

Abstract

Interventional pulmonology (IP) has evolved over the past decade from an obscure subspecialty in pulmonary medicine to a recognized discipline offering advanced consultative and procedural services to patients with thoracic malignancy, anatomic airway disease, and pleural disease. Innovative interventions are now also available for diseases not traditionally treated procedurally, such as asthma and emphysema. The IP field has established certification examinations and training standards for IP training programs in an effort to enhance training quality and ensure competency. Validating new technology and proving its cost-effectiveness and effect on patient outcomes present the biggest challenge to IP as the health-care environment marches toward value-based health care. High-quality research is now thriving in IP and promises to elevate its practice into patient-centric evidence-based care.

Original language	English (US)
Pages (from-to)	724-736
Number of pages	13
Journal	CHEST
Volume	157
Issue number	3
DOIs	https://doi.org/10.1016/j.chest.2019.10.013
State	Published - Mar 2020

Funding

Financial/nonfinancial disclosures: The authors have reported to CHEST the following: M. M. W. has served as a consultant to Boston Scientific; Nuvaira Inc; Olympus Corporation; and Veracyte, Inc and has served as a reviewer on the Data Safety Monitoring Board for CSA Medical Inc. F. J. F. H. has served as a consultant to Broncus Medical, Inc; BTG plc; Olympus Corporation; Pulmonx Inc; and Uptake Medical and has received research funding from them. A. C. has served as a consultant to Auris Health, Inc; Boston Scientific; and Olympus Corporation and has received research funding from Auris Health, Inc; Boston Scientific ; Olympus Corporation; and Veran Medical Technologies. G. C. has served as a consultant to Boston Scientific; Medtronic plc; Pinnacle Biologics, Inc; and Restor3D and has received research funding from Intuitive Surgical Inc and Pinnacle Biologics, Inc. L. Y. has served as a consultant to AstraZeneca; Boston Scientific; Olympus Corporation; Veracyte, Inc; and Veran Medical Technologies.

Keywords

bronchoscopy
interventional pulmonology
lung biopsy
lung neoplasm

ASJC Scopus subject areas

Critical Care and Intensive Care Medicine
Cardiology and Cardiovascular Medicine
Pulmonary and Respiratory Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.chest.2019.10.013

Cite this

@article{5e152242074f4a3ea2e88380a3e96b2d,

title = "State of the Art: Interventional Pulmonology",

abstract = "Interventional pulmonology (IP) has evolved over the past decade from an obscure subspecialty in pulmonary medicine to a recognized discipline offering advanced consultative and procedural services to patients with thoracic malignancy, anatomic airway disease, and pleural disease. Innovative interventions are now also available for diseases not traditionally treated procedurally, such as asthma and emphysema. The IP field has established certification examinations and training standards for IP training programs in an effort to enhance training quality and ensure competency. Validating new technology and proving its cost-effectiveness and effect on patient outcomes present the biggest challenge to IP as the health-care environment marches toward value-based health care. High-quality research is now thriving in IP and promises to elevate its practice into patient-centric evidence-based care.",

keywords = "bronchoscopy, interventional pulmonology, lung biopsy, lung neoplasm",

author = "Wahidi, \{Momen M.\} and Herth, \{Felix J.F.\} and Alexander Chen and George Cheng and Lonny Yarmus",

note = "Funding Information: Financial/nonfinancial disclosures: The authors have reported to CHEST the following: M. M. W. has served as a consultant to Boston Scientific; Nuvaira Inc; Olympus Corporation; and Veracyte, Inc and has served as a reviewer on the Data Safety Monitoring Board for CSA Medical Inc. F. J. F. H. has served as a consultant to Broncus Medical, Inc; BTG plc; Olympus Corporation; Pulmonx Inc; and Uptake Medical and has received research funding from them. A. C. has served as a consultant to Auris Health, Inc; Boston Scientific; and Olympus Corporation and has received research funding from Auris Health, Inc; Boston Scientific ; Olympus Corporation; and Veran Medical Technologies. G. C. has served as a consultant to Boston Scientific; Medtronic plc; Pinnacle Biologics, Inc; and Restor3D and has received research funding from Intuitive Surgical Inc and Pinnacle Biologics, Inc. L. Y. has served as a consultant to AstraZeneca; Boston Scientific; Olympus Corporation; Veracyte, Inc; and Veran Medical Technologies. Publisher Copyright: {\textcopyright} 2019 American College of Chest Physicians",

year = "2020",

month = mar,

doi = "10.1016/j.chest.2019.10.013",

language = "English (US)",

volume = "157",

pages = "724--736",

journal = "CHEST",

issn = "0012-3692",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - State of the Art

T2 - Interventional Pulmonology

AU - Wahidi, Momen M.

AU - Herth, Felix J.F.

AU - Chen, Alexander

AU - Cheng, George

AU - Yarmus, Lonny

N1 - Funding Information: Financial/nonfinancial disclosures: The authors have reported to CHEST the following: M. M. W. has served as a consultant to Boston Scientific; Nuvaira Inc; Olympus Corporation; and Veracyte, Inc and has served as a reviewer on the Data Safety Monitoring Board for CSA Medical Inc. F. J. F. H. has served as a consultant to Broncus Medical, Inc; BTG plc; Olympus Corporation; Pulmonx Inc; and Uptake Medical and has received research funding from them. A. C. has served as a consultant to Auris Health, Inc; Boston Scientific; and Olympus Corporation and has received research funding from Auris Health, Inc; Boston Scientific ; Olympus Corporation; and Veran Medical Technologies. G. C. has served as a consultant to Boston Scientific; Medtronic plc; Pinnacle Biologics, Inc; and Restor3D and has received research funding from Intuitive Surgical Inc and Pinnacle Biologics, Inc. L. Y. has served as a consultant to AstraZeneca; Boston Scientific; Olympus Corporation; Veracyte, Inc; and Veran Medical Technologies. Publisher Copyright: © 2019 American College of Chest Physicians

PY - 2020/3

Y1 - 2020/3

N2 - Interventional pulmonology (IP) has evolved over the past decade from an obscure subspecialty in pulmonary medicine to a recognized discipline offering advanced consultative and procedural services to patients with thoracic malignancy, anatomic airway disease, and pleural disease. Innovative interventions are now also available for diseases not traditionally treated procedurally, such as asthma and emphysema. The IP field has established certification examinations and training standards for IP training programs in an effort to enhance training quality and ensure competency. Validating new technology and proving its cost-effectiveness and effect on patient outcomes present the biggest challenge to IP as the health-care environment marches toward value-based health care. High-quality research is now thriving in IP and promises to elevate its practice into patient-centric evidence-based care.

AB - Interventional pulmonology (IP) has evolved over the past decade from an obscure subspecialty in pulmonary medicine to a recognized discipline offering advanced consultative and procedural services to patients with thoracic malignancy, anatomic airway disease, and pleural disease. Innovative interventions are now also available for diseases not traditionally treated procedurally, such as asthma and emphysema. The IP field has established certification examinations and training standards for IP training programs in an effort to enhance training quality and ensure competency. Validating new technology and proving its cost-effectiveness and effect on patient outcomes present the biggest challenge to IP as the health-care environment marches toward value-based health care. High-quality research is now thriving in IP and promises to elevate its practice into patient-centric evidence-based care.

KW - bronchoscopy

KW - interventional pulmonology

KW - lung biopsy

KW - lung neoplasm

UR - https://www.scopus.com/pages/publications/85079883314

UR - https://www.scopus.com/inward/citedby.url?scp=85079883314&partnerID=8YFLogxK

U2 - 10.1016/j.chest.2019.10.013

DO - 10.1016/j.chest.2019.10.013

M3 - Review article

C2 - 31678309

AN - SCOPUS:85079883314

SN - 0012-3692

VL - 157

SP - 724

EP - 736

JO - CHEST

JF - CHEST

IS - 3

ER -

State of the Art: Interventional Pulmonology

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this